Core Viewpoint - The company has partially completed the subscription agreement B on December 7, 2025, issuing 1.0037 million new shares at HKD 12.00 per share, while agreeing to terminate the remaining subscription of 2.1513 million shares without any claims between the parties involved [1] Group 1 - The company and subscriber B mutually agreed to terminate the remaining subscription of 2.1513 million shares, rendering all rights and obligations void, with no claims allowed between the parties [1] - The board believes that the termination of the remaining shares will not have any significant adverse impact on the company's existing business, operations, or financial condition [1] Group 2 - Subscriber C failed to fulfill its obligations under subscription agreement C by December 7, 2025, leading the company to terminate this agreement as well [1] - Similar to agreement B, the termination of agreement C also results in all rights and obligations being void, with no claims permitted between the parties [1] - The board asserts that the termination of subscription agreement C will not significantly affect the company's current business, operations, or financial status [1]
圣诺医药-B：部分完成根据一般授权认购新股份及终止认购协议